Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Frontiers in Immunology
|
May 26, 2022
Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
Hong Mu-Mosley, Lauren Ostermann, Muharrem Muftuoglu, et al.
Oncoimmunology
|
May 13, 2024
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities
Hong Mu-Mosley, Mitchell S von Itzstein, Farjana Fattah, et al.
Translational Lung Cancer Research
|
December 10, 2025
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancer
Mary E Gwin, Mitchell S von Itzstein, Jialiang Liu, et al.
Cancer Immunology, Immunotherapy : CII
|
May 14, 2026
Correction: Metabolic syndrome and immune-related adverse events
Katherine Lei, Meera J Patel, Jialiang Liu, et al.
Cancer Immunology, Immunotherapy : CII
|
January 27, 2026
Metabolic syndrome and immune-related adverse events
Katherine Lei, Meera J Patel, Jialiang Liu, et al.
Journal for Immunotherapy of Cancer
|
December 9, 2021
Humoral and cellular correlates of a novel immune-related adverse event and its treatment
Amrit S Gonugunta, Mitchell S von Itzstein, Hong Mu-Mosley, et al.
Leukemia
|
April 21, 2023
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML
Yannan Jia, Weiguo Zhang, Mahesh Basyal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer
Mitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Clinical Chemistry and Laboratory Medicine
|
October 26, 2022
Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study
Antigona Ulndreaj, Davor Brinc, Mehmet Altan, et al.
Journal for Immunotherapy of Cancer
|
October 28, 2025
Genetic haplotypes in <i>VWA8, OSBPL6,</i> and <i>ADAMTS9-AS2</i> are associated with immune-related adverse effects in ICI-treated patients with cancer
Prithvi Raj, Jialiang Liu, Chengsong Zhu, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Frontiers in Immunology
|
May 26, 2022
Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
Hong Mu-Mosley, Lauren Ostermann, Muharrem Muftuoglu, et al.
Oncoimmunology
|
May 13, 2024
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities
Hong Mu-Mosley, Mitchell S von Itzstein, Farjana Fattah, et al.
Translational Lung Cancer Research
|
December 10, 2025
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancer
Mary E Gwin, Mitchell S von Itzstein, Jialiang Liu, et al.
Cancer Immunology, Immunotherapy : CII
|
May 14, 2026
Correction: Metabolic syndrome and immune-related adverse events
Katherine Lei, Meera J Patel, Jialiang Liu, et al.
Cancer Immunology, Immunotherapy : CII
|
January 27, 2026
Metabolic syndrome and immune-related adverse events
Katherine Lei, Meera J Patel, Jialiang Liu, et al.
Journal for Immunotherapy of Cancer
|
December 9, 2021
Humoral and cellular correlates of a novel immune-related adverse event and its treatment
Amrit S Gonugunta, Mitchell S von Itzstein, Hong Mu-Mosley, et al.
Leukemia
|
April 21, 2023
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML
Yannan Jia, Weiguo Zhang, Mahesh Basyal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer
Mitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Clinical Chemistry and Laboratory Medicine
|
October 26, 2022
Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study
Antigona Ulndreaj, Davor Brinc, Mehmet Altan, et al.
Journal for Immunotherapy of Cancer
|
October 28, 2025
Genetic haplotypes in <i>VWA8, OSBPL6,</i> and <i>ADAMTS9-AS2</i> are associated with immune-related adverse effects in ICI-treated patients with cancer
Prithvi Raj, Jialiang Liu, Chengsong Zhu, et al.
Page
of 2